Nature Biotechnology, Published online: 04 June 2026; doi:10.1038/s41587-026-03182-5
The significance of the first FDA-approved PROTAC lies not in proving that targeted protein degradation is superior to conventional therapies, but in proving that degrading proteins is possible as a therapeutic.